1: Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman

KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K,

Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH

Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin R.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced

Melanoma. J Clin Oncol. 2015 May 26. pii: JCO.2014.58.3377. [Epub ahead of print]

PubMed PMID: 26014293.

2: Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for

melanoma. Curr Treat Options Oncol. 2015 Mar;16(3):326. doi:

10.1007/s11864-014-0326-0. PubMed PMID: 25777572.

3: Agarwala SS. Intralesional therapy for advanced melanoma: promise and

limitation. Curr Opin Oncol. 2015 Mar;27(2):151-6. doi:

10.1097/CCO.0000000000000158. PubMed PMID: 25629369; PubMed Central PMCID:

PMC4323546.

4: Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM,

Preville X, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch:: Oncolytic viruses

for cancer therapy. Oncoimmunology. 2014 Jun 1;3:e28694. eCollection 2014.

Review. PubMed PMID: 25097804; PubMed Central PMCID: PMC4091053.

5: Kaufman HL, Ruby CE, Hughes T, Slingluff CL Jr. Current status of

granulocyte-macrophage colony-stimulating factor in the immunotherapy of

melanoma. J Immunother Cancer. 2014 May 13;2:11. doi: 10.1186/2051-1426-2-11.

eCollection 2014. Review. PubMed PMID: 24971166; PubMed Central PMCID:

PMC4072479.

6: Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for

melanoma. Am J Clin Dermatol. 2014 Aug;15(4):323-37. doi:

10.1007/s40257-014-0083-7. Review. PubMed PMID: 24928310.

7: Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere

J. Oncolytic virotherapy as emerging immunotherapeutic modality: potential of

parvovirus h-1. Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092.

eCollection 2014. Review. PubMed PMID: 24822170; PubMed Central PMCID:

PMC4013456.

8: Saraceni MM, Khushalani NI, Jarkowski A 3rd. Immunotherapy in Melanoma: Recent

Advances and Promising New Therapies. J Pharm Pract. 2014 Mar 27. [Epub ahead of

print] PubMed PMID: 24674910.

9: Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 vectors for gene

therapy. Methods Mol Biol. 2014;1144:63-79. doi: 10.1007/978-1-4939-0428-0\_5.

PubMed PMID: 24671677.

10: Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev Vaccines. 2013

Oct;12(10):1155-72. doi: 10.1586/14760584.2013.836912. Review. PubMed PMID:

24124877.

11: Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G,

Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology.

2013 Jun 1;2(6):e24612. Epub 2013 Apr 16. PubMed PMID: 23894720; PubMed Central

PMCID: PMC3716755.

12: Galluzzi L, Lugli E. Cancer immunotherapy turns viral. Oncoimmunology. 2013

Apr 1;2(4):e24802. PubMed PMID: 23734338; PubMed Central PMCID: PMC3654608.

13: Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012 Jul

10;30(7):658-70. doi: 10.1038/nbt.2287. Review. PubMed PMID: 22781695; PubMed

Central PMCID: PMC3888062.